Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

DNA Analysis

October 28, 2010 5:21 am | Drug Discovery & Development | Product Releases | Comments

ZyGEM Corp. Ltd., announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity and cost of conducting DNA testing.


Lead Optimization Tool

October 28, 2010 5:19 am | Product Releases | Comments

InhibOx Ltd announces LOx 2.0 - a flexible system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds.


Stem Cells + Protein = Cancer

October 28, 2010 5:16 am | News | Comments

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.


Concerns Raised About 'Healthy' Antioxidants

October 28, 2010 5:14 am | News | Comments

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants — including those with the apparent ability to prevent cancer — may actually aggravate or even cause cancer in some individuals.


GlobeImmune Expands GI-5005 Trial

October 28, 2010 5:11 am | News | Comments

GlobeImmune Inc. announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus infection. The company previously reported a 60% improvement in sustained virologic response.


Ligocyte VLP Candidate Performs Well in Phase 1/2

October 28, 2010 5:08 am | News | Comments

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing vaccine products, announced positive results from a Phase 1/2 challenge study of its norovirus virus-like particle (VLP) vaccine candidate.


Sanofi Invests $10M In Regulus

October 28, 2010 5:05 am | News | Comments

Regulus Therapeutics Inc. announced that they have received a $10 million equity investment from sanofi-aventis. The investment makes sanofi-aventis the third investor in Regulus, along with its founding companies Alnylam and Isis.


Michigan to Receive $4.7M of Glaxo Settlement

October 28, 2010 5:01 am | News | Comments

Michigan Attorney General Mike Cox says the state will get a $4.7 million share of a $750 million settlement of claims that GlaxoSmithKline distributed adulterated drugs.


CDC Panel Recommends Meningitis Booster

October 28, 2010 5:00 am | by Mike Stobbe | News | Comments

Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said.


Gates Foundations Giving Millions in Seed Money

October 28, 2010 4:58 am | by Donna Gordon Blankinship | News | Comments

A night light that scares away mosquitoes possibly carrying malaria is among nine ideas the Bill & Melinda Gates Foundation thinks are worth more research dollars, after giving more than 300 scientists seed money to take an initial look at some far-out notions.


Affymetrix Revenue Down 5%

October 28, 2010 4:55 am | News | Comments

Affymetrix, Inc., reported its operating results for the third quarter of 2010. Total revenue for the quarter was $74.0 million as compared to total revenue of $78.2 million in the third quarter of 2009.


Elan Loses $43M In 3rd Quarter

October 28, 2010 4:52 am | News | Comments

Irish drugmaker Elan Corp. reported a third-quarter net loss as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.


Emerging Markets Drive Sanofi Profits Up

October 28, 2010 4:49 am | by Greg Keller | News | Comments

French pharmaceutical company Sanofi-Aventis SA said its net profit rose 13 percent in the third quarter thanks to strong demand in emerging markets and acquisitions in the consumer health care field.


AZ Profit Sinks on Seroquel Settlement

October 28, 2010 4:46 am | News | Comments

Pharmaceutical company AstraZeneca on Thursday reported a 27 percent drop in third-quarter profit as it set aside nearly half a billion dollars to settle claims that its anti-psychotic drug Seroquel has harmful side-effects.


Bayer Earnings Jump 12%

October 28, 2010 4:45 am | by Geir Moulson | News | Comments

Bayer AG's third-quarter earnings rose 12 percent as sales of farm products and high-tech materials boosted revenue at the pharmaceutical and chemical company, helping balance out slower growth at its drug division.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.